Literature DB >> 2690089

Present progress and future development in the therapy for Alzheimer's disease.

E Giacobini1, R Becker.   

Abstract

The following is a review of the present progress and future development in the experimental therapy of Alzheimer disease (AD). Four different approaches are considered, first a molecular genetic one, second neuropeptide delivery, third trophic factors administration and fourth a cholinergic approach. Advantages and disadvantages of presently applied therapeutical experiments are analyzed and discussed together with the author's own experience and results.

Entities:  

Mesh:

Year:  1989        PMID: 2690089

Source DB:  PubMed          Journal:  Prog Clin Biol Res        ISSN: 0361-7742


  3 in total

Review 1.  Potential role of muscarinic agonists in Alzheimer's disease.

Authors:  E E Avery; L D Baker; S Asthana
Journal:  Drugs Aging       Date:  1997-12       Impact factor: 3.923

Review 2.  Optimal management of behavioural disorders associated with dementia.

Authors:  C A Class; L Schneider; M R Farlow
Journal:  Drugs Aging       Date:  1997-02       Impact factor: 4.271

3.  PD 142676 (CI 1002), a novel anticholinesterase and muscarinic antagonist.

Authors:  M R Emmerling; V E Gregor; R D Schwarz; J D Scholten; M J Callahan; C Lee; C J Moore; C Raby; W J Lipinski; R E Davis
Journal:  Mol Neurobiol       Date:  1994 Aug-Dec       Impact factor: 5.590

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.